OrbiMed — 2021 Investments
9 investments dated 2021 · listed companies and verified rows first · show all
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)in
Co-investorsAndreessen HorowitzAvoro Capital AdvisorsMenlo VenturesRA CapitalAvoro Ventures
Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.
AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US
Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))inChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in
Co-investors20/20 HealthCare Partners LLCBosch VenturesNew Era Capital PartnersPeregrine VenturesPitangoQuark Venture Inc.+2 more
Chemomab Therapeutics is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases.
BiotechTel Aviv
Neil Harris Cohen(Director)Jill Quigley(Director)Sigal Fattal(Executive Officer)Adi Mor(Executive Officer, Director)Alan Charles Moses(Director)Matthew Frankel(Executive Officer)
Board seatStephen Squinto· per SEC Form D
Co-investorsAltium Capital
BiotechPennington, US
Chris Duke(Mr. Duke is the Chief Operating Officer of the Issuer.)Dale Ludwig(Mr. Ludwig is the Chief Scientific Officer)Anuj Goswami(Mr. Goswami is the General Counsel and Secretary)Claudine Prowse(Ms. Prowse is the Chief Financial Officer)Gary Sender(Director)Julie Hambleton(Director)
Board seatChau Khuong· per SEC Form D · $55M raise · filed Dec 2021
Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)in
Board seatKevin KochKlaus Veitinger· per SEC Form D
Co-investors5AM VenturesSamsara BioCapitalvenBio PartnersVivo CapitalvenBio Global StrategicWestlake Village BioPartners
Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.
Digital HealthMedical DevicesWellness & FitnessPleasanton, US
Shri Raghunathan(Founder)in
Board seatChau Khuong· per SEC Form D
Co-investorsAngelini VenturesBlue Venture FundsTreo Ventures, LlcZühlke VenturesBridge BankSandbox Clinical Ventures+1 more
BiotechChicago, US
Rand Sutherland(Director)James Sullivan(Executive Officer, Director)in
BoardBernard Davitian(Director)Uya Chuluunbaatar(Director)
Board seatJonathan SilversteinStephen SquintoMona Ashiya· per SEC Form D
Co-investorsPontifax Venture Capital
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)Ryan B. Corcoran(Director, Promoter)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersNextech InvestVida VenturesDigitalis VenturesNVIDIA
Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.
BiotechSan Diego, US
Yi Liu(Executive Officer, Director)Lynn Yang(Director)
BoardCarl Gordon(Director)in
Co-investorsEcoR1 CapitalRoche Venture Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.